Cargando…
YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway
BACKGROUND: Novel-targeted therapies are in rapid development for the treatment of acute lymphoblastic leukemia (ALL) to overcome resistance and decrease toxicity. Survivin, a member of the inhibitor of apoptosis gene family and chromosome passenger complex, is critical in a variety of human cancers...
Autores principales: | Chang, Bill H, Johnson, Kara, LaTocha, Dorian, Rowley, Joelle S J, Bryant, Jade, Burke, Russell, Smith, Rebecca L, Loriaux, Marc, Müschen, Markus, Mullighan, Charles, Druker, Brian J, Tyner, Jeffrey W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408565/ https://www.ncbi.nlm.nih.gov/pubmed/25895498 http://dx.doi.org/10.1186/s13045-015-0132-6 |
Ejemplares similares
-
Aurora A kinase as a target for therapy in TCF3-HLF rearranged acute lymphoblastic leukemia
por: Leonard, Jessica, et al.
Publicado: (2021) -
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
por: Glover, Jason M, et al.
Publicado: (2012) -
YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
por: Na, Young-Soon, et al.
Publicado: (2012) -
YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network
por: Véquaud, Eloïse, et al.
Publicado: (2015) -
Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023)